NEW DOJ/OIG COMPLIANCE BEST PRACTICES

Putting Protocols into Action: Key Differences, Potential Pitfalls, and New Implementation Hurdles

May 9, 2024 9:45am

Gwen Chapman
Chief Compliance Officer
Illumina, Inc.

Mason Hubbard
Senior Anti-Corruption Counsel
Gilead Sciences

Margaret Price
Vice President, Chief Compliance Officer
Atricure

Amid continuing increased DOJ enforcement postures, and newly introduced U.S. Department of Health and Human Services (OIG) compliance program guidelines, how are life science multinationals designing compliance program updates to meet both DOJ/OIG expectations? What are the key differences and compliance nuances between these two compliance program guidance measures and what are the critical implementation tips, tools, and roadblocks to look out for?